Open AccessAntibiotic resistance of Helicobacter pylori to 16 antibiotics in clinical patients
Author(s) -
Shao Yongfu,
Lu Rongdan,
Yang Yunben,
Xu Qiancheng,
Wang Bojun,
Ye Guoliang
Publication year - 2018
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.22339
Subject(s) - levofloxacin , clarithromycin , amoxicillin , medicine , helicobacter pylori , antibiotics , antibiotic resistance , moxifloxacin , rifampicin , tinidazole , ciprofloxacin , microbiology and biotechnology , metronidazole , agar dilution , drug resistance , biology , minimum inhibitory concentration
Background Resistance of Helicobacter pylori ( H. pylori ) to antibiotics is increasing worldwide. To determine the status of H. pylori resistance and its patterns in clinical patients, an investigation utilizing susceptibility testing for commonly used antibiotics was needed. Methods Total of 2283 H. pylori strains were collected from 2013 to 2016. The resistance and its patterns of these strains were tested by agar dilution method. The resistance rate and minimal inhibition concentration ( MIC ) in different gender groups were also analyzed. Results The overall resistance rates were as following: amoxicillin (1.58%), clarithromycin (22.73%), levofloxacin (24.75%), furazolidone (1.49%), doxycycline (9.20%), cefetamet (97.20%), ceftriaxone (49.60%), cefuroxime (25.20%), gentamicin (3.73%), azithromycin (85.60%), rifampicin (2.80%), metronidazole (92.53%), ornidazole (94.27%), tinidazole (87.20%), ciprofloxacin (43.20%), and moxifloxacin (38.53%). There were only 64.08% strains pan‐susceptible to amoxicillin, clarithromycin, levofloxacin, and furazolidone, followed by mono resistance (23.17%), double resistance (11.13%), triple resistance (1.36%), and quadruple resistance (0.26%). Significant differences in the resistance rate and MIC were also observed in different gender groups. Conclusion Antibiotic resistance trends of H. pylori is increasing in clinical patients. With the increasing resistance, it is imperative to individualized therapy based on the results of drug susceptibility testing.